Skip to Content

MSMB Capital Management Proposes Acquisition of SeraCare for $4.25 Per Share

Offer Represents a 22% Premium to Stock Price

NEW YORK--(BUSINESS WIRE)--Jun 23, 2011 - MSMB Capital Management, a fund specializing in long-term strategic investments in healthcare and biotechnology businesses, today announced that it has made a proposal to the Board of Directors of SeraCare Life Sciences, Inc. (NASDAQ: SRLS) to acquire all the outstanding common stock of SeraCare for $4.25 per share or an aggregate of $82 million. This proposal represents an approximate 22% premium above the closing price of SeraCare stock of $3.49 on June 22nd, 2011.

MSMB's offer is conditioned on completion of cursory due diligence and other customary provisions. MSMB's offer is not subject to any financing condition.

“While I appreciate the professional response SeraCare management has provided to the offer I privately communicated, I now believe it is in SeraCare's shareholders' best interest for this process to become public”, said Martin Shkreli, Chief Investment Officer of MSMB Capital Management LLC.

Shkreli added, “My hope is the Board of Directors and I can come to a friendly conclusion to this matter. However, MSMB reserves the right to take any steps it deems necessary to maximize shareholder value if a timely conclusion is not reached.”

The full text of the letter that MSMB Capital Management sent to SeraCare's Board of Directors can be found below:

About MSMB Capital

MSMB Capital is an investment firm focused on global healthcare and biotechnology opportunities and long-term investments. MSMB identifies and pursues investments in both the private and public markets. MSMB identifies investment opportunities and seeks to maximize value and create opportunities.

June 23rd, 2011

The Board of Directors

SeraCare Life Sciences, Inc.

37 Birch Street

Millford, MA 01757

Ladies and Gentlemen:

On behalf of MSMB Capital Management (“MSMB”), of which I am Chief Investment Officer, I am writing to offer that MSMB acquire SeraCare Life Sciences, Inc. (the “Company”) in a transaction beneficial to all of the Company's stockholders and stakeholders.

MSMB is a long-term stockholder of the Company and wants to help other stockholders maximize their investment in the Company by providing them an alternative that provides immediate liquidity.

Although we believe that the Company's current management performed admirably in steering the Company out of bankruptcy several years ago, the Company's stock price has stagnated over the past 18 months. Specifically, we believe that if we had not been actively acquiring shares of the Company's common stock over the last several months, the Company's stock price would be much lower. Given the Company's stock price and management's inability to grow the Company's business, we are offering to acquire all of the outstanding shares of the Company's common stock, other than those owned by us, at a price of $4.25 per share. This proposal represents a 22% premium above the closing price of the Company's stock of $3.49 on June 22nd, 2011, and a 24% premium based on the trailing twenty-day average closing price. We strongly believe that the Board of Directors should find our offer to be fair and in the best interests of the Company's stockholders.

Due to the significant value that MSMB believes the Company represents, MSMB could be prepared to increase the price per share mentioned above if (a) it is allowed time and access in order to conduct due diligence and that due diligence validates certain understandings about the Company and its prospects and (b) MSMB is able to negotiate a definitive acquisition agreement containing customary representations, warranties, covenants and closing conditions. MSMB is prepared to begin the due diligence process immediately.

We believe the support of the Company's senior management is important to the success of the Company and hope to work with them through this process and following the consummation of a transaction.

While our offer is subject to customary closing conditions and a cursory due diligence period, it is not subject to any financing condition. Our proposal is contingent on the Company entering into a definitive agreement with MSMB prior to July 29th, 2011.

It is imperative that the Company be sold now and further erosion to stockholder value be prevented. The proposal outlined above adheres to a clear timeline, provides stockholders with a price no less than $4.25, and allows for a higher price if one is warranted. Our offer is compelling and provides the Company's stockholders an immediate and certain path to a premium, all-cash transaction that will eliminate future market risk as well as the risk of future value destruction.

It is our strong preference to work together immediately to negotiate a definitive merger agreement. From our perspective, the benefits to your employees and shareholders should provide a meaningful impetus for you to seriously investigate this opportunity. Nonetheless, if you choose not to engage with us, we are prepared to proceed promptly with an offer directly to your stockholders. We and our counsel, Katten Muchin Rosenman LLP, are available immediately to discuss the terms of our proposal and to negotiate a definitive agreement with the Company. We hope to receive a favorable response from you promptly and we are confident that, with the Company's cooperation, we can quickly reach a definitive agreement.

We look forward to discussing the above with you at your earliest convenience. We request a response from you to our proposal by 5:00 pm on July 11th, 2011. If you do not respond by that time, we reserve the right to take whatever steps we deem necessary to preserve and maximize stockholder value.

This letter is not intended to create or reflect any legally binding obligation by us regarding the proposed transaction and no such obligation shall arise unless and until a mutually acceptable definitive agreement is executed.


/s/ Martin Shkreli

Martin Shkreli

Contact: MSMB Capital Management LLC
Kevin Mulleady, 212-983-0069
Chief Executive Officer



Posted: June 2011